119
Participants
Start Date
March 2, 2021
Primary Completion Date
May 28, 2024
Study Completion Date
May 28, 2024
satralizumab
Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years
azathioprine (AZA)
Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)
mycophenolate mofetil (MMF)
Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day
oral corticosteroids
Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day
Taipei Veterans General Hospital, Taipei
Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv. Naum EAD, Sofia
Jahn Ferenc Del-Pesti Korhaz es Rendelointezet, Budapest
University Multiprofile Hospital for Active Treatment Aleksandrovska EAD, Sofia
UMHAT 'Dr. Georgi Stranski', EAD, Pleven
National Taiwan University Hospital, Taipei
Jefferson Hospital For Neuroscience; Jefferson Neurology Associates, Philadelphia
Communal NPE Vinnytsia Reg. Clin. Psychoneurolog. Hosp. n.a. O.I. Yushchenko of Vinnytsia RC, Vinnytsia
Hosp. Clinico San Carlos, Madrid
The Neurological Institute PA, Charlotte
Clinical Hospital Centre Osijek, Osijek
Columbus Research and Wellness, Columbus
University of Miami, Miami
Bilim University Medical Faculty Florence Nightingale Hospital, Istanbul
Children's Hospital of Alabama, Birmingham
China Medical University Hospital, North Dist.
OhioHealth Research Institute, Columbus
Ruhr Universitat Bochum, Bochum
Communal Nonprofit enterprise Ternopil Regional Clinical Psychoneurological Hospital of TRC, Ternopil
Wayne State University; UHC-4H, Detroit
Municipal Non-Profit Enterprise City Clinical Hospital #16 of Dnipro City Council, Dnipro
Hospital Kuala Lumpur, Kuala Lumpur
Consultants in Neurology Ltd, Northbrook
University of Chicago, Chicago
OSF Saint Francis Medical Center, Peoria
Municipal Non-Commercial Enterprise Odesa RMC for Mental Health of Odessa Regional Council, Odesa
University of Kansas Medical Center, Kansas City
National Cheng Kung University Hospital, Tainan City
Central Texas Neurology Consultants, Round Rock
Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Catania
SC Clubul Sanatatii SRL, Campulung Muscel
University of Texas Southwestern Medical Center, Dallas
MS Clinical Trials Group, Vancouver
Centre hospitalier de l'Universite de Montreal (CHUM), Montreal
Azienda Ospedaliera Sant'Andrea, Rome
Kyushu University Hospital, Fukuoka
Tohoku University Hospital, Miyagi
Niigata University Medical & Dental Hospital, Niigata
Osaka University Hospital, Osaka
Kindai University Hospital, Osaka
Tokyo Women's Medical University Hospital, Tokyo
National Center of Neurology and Psychiatry, Tokyo
NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS, Katowice
M.A. - LEK A. M. Maciejowscy SC. Centrum Terapii SM, Katowice
Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie; Klinika Neurologii, Lublin
Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny; Klinika Neurologii, Warsaw
Instytut Psychiatrii i Neurologii, Warsaw
Miedzyleski Szpital Specjalistyczny w Warszawie, Warsaw
San Juan MS Center, Guaynabo
Korea University Anam Hospital, Seoul
Asan Medical Center - PPDS, Seoul
Hospital Clinic de Barcelona, Barcelona
National Hospital For Neurology and Neurosurgery, London
Hoffmann-La Roche
INDUSTRY